Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novavax, a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases, has appointed Gregory Glenn as its new chief scientific officer. He will report to Rahul Singhvi, president and CEO of of the company.
Subscribe to our email newsletter
Earlier, Dr Glenn was the chief scientific officer and founder of IOMAI Corporation (now Intercell), an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research.
Mr Singhvi said: “Greg Glenn is a recognised innovator and authority on vaccines, vaccine delivery and adjuvants. He brings to Novavax considerable experience in the discovery, development and clinical evaluation of a wide variety of vaccines to prevent diseases such as pandemic influenza, tetanus, malaria, HIV and cancer.”
Dr Glenn said: “I am excited to join a very talented team and help them apply Novavax’s technology platform to the discovery and development of novel vaccines.
“The use of virus-like particles to mimic live viruses is a very promising approach to preventing the spread of infectious diseases. I look forward to supporting the development and application of this very promising approach to disease prevention.”